ArticleNanomaterials (Basel, Switzerland)2026
Discriminative Sensing of Structurally Similar Neurotransmitters via In-TBAPy MOF Arrays.
Article in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The accurate discrimination of structurally analogous neurotransmitters remains a formidable challenge due to their high structural similarity and overlapping chemical properties. To address the limitations of low specificity in single-probe sensors and the fabrication complexity of multi-component arrays, we developed a simplified fluorescence sensing array based on a single pyrene-functionalized MOF, In-TBAPy. This strategy leverages the distinctive monomer-to-excimer luminescence transition of In-TBAPy, triggered by the tunable π-π stacking of pyrene units within the crystalline framework. The results demonstrate that the array, integrated with Linear Discriminant Analysis (LDA) across four optimized emission channels, achieves a classification accuracy of 93.75% in identifying four highly similar neurotransmitters: serotonin (5-HT), dopamine (DA), adrenaline (A), and norepinephrine (NA). Notably, the sensing platform exhibits exceptional robustness in simulated physiological environments and complex multi-analyte mixtures, enabling reliable quantitative analysis: 0-100 μM for 5-HT and adrenaline (A), 0-40 μM for dopamine (DA), and 0-80 μM for norepinephrine. Mechanistic studies suggest that the differential quenching of monomer and excimer peaks stems from the synergistic effect of competitive absorption and host-guest interactions. This work effectively overcomes the cross-interference issues of traditional sensors and validates a high-efficiency solution for high-throughput neurotransmitter analysis using a single-material-based array strategy, significantly reducing operational costs and preparation time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.